MULTIMEDIA AVAILABLE:

http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5341254

CHICAGO--(BUSINESS WIRE)--Feb. 26, 2007--At Pittcon 2007, Bruker AXS today announces several new X-ray and optical emission spectroscopy (OES) products and solutions for life-science and advanced materials research, as well as for industrial analysis:

• The new MICROSTAR ULTRA(TM), an ultra-bright laboratory X-ray source for structural biology, is comparable in brightness to many second-generation synchrotron beamlines. Utilizing novel electron optics and the revolutionary new Hypercool(TM) cooling design (patent applied for), the MICROSTAR ULTRA produces unrivalled X-ray intensities, which are beneficial for all aspects of in-house crystallographic research, from high-throughput crystal screening to structure determinations with SAD phasing.
• The new and unique I(mu)S(TM) X-ray microfocus source for crystallography and X-ray diffraction (XRD) is the result of a joint effort between Bruker AXS and Incoatec GmbH. The I(mu)S is the brightest sealed-tube X-ray generator ever, and incorporates high-performance Quazar(TM) multilayer X-ray optics. The I(mu)S offers numerous customer benefits that include no moving parts, a long lifetime without maintenance, excellent stability, no water-cooling and low cost of ownership.
• The next-generation liquid nitrogen-free XFlash(R) 4030 Silicon Drift Detector (SDD) for EDS microanalysis has a larger area of 30 mm2 and can achieve energy resolution of 133 eV at 100,000 counts per second. The XFlash 4030 detector can be positioned very close to the sample and can achieve up to a threefold increase in detected signal at the same beam current. This is ideal for low beam current applications and for sensitive samples in electron microscopes, or for higher throughput in EDS analysis.
• The significantly enhanced S2 RANGER(TM) EDXRF spectrometer now also incorporates an XFlash(R) SDD detector, and can analyze all elements from sodium to uranium in concentrations from 100% down to ppm levels. Due to the superior energy resolution at high count rates, the new S2 RANGER with XFlash SDD offers better analytical performance for many petrochemical, metals analysis and other industrial applications.
• The new RoHS-QUANT(TM) XRF solution now offers a more reliable, accurate and faster method for quantitatively screening RoHS-regulated elements in electronic components. The new RoHS-QUANT solution can be used with Bruker AXS' S2 RANGER, S4 EXPLORER and S4 PIONEER XRF systems.
• The new Q8 CORONADO(TM) automated solution for metal foundries combines the proven high-performance Q8 MAGELLAN(TM) spark OES system with fully automated sample preparation. The affordable, compact Q8 CORONADO ensures reliable, rapid analysis of ferrous and non-ferrous samples with automated sample preparation, OES elemental analysis and data archiving for consistently high analytical quality and shorter sample turn-around times at low operational cost.
• The TRACER III-V is the world's first handheld vacuum XRF instrument with excellent light-element analysis capabilities and flexible software for museum, art and conservation analysis.

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc., Bruker AXS Inc. and Bruker Optics Inc. Bruker AXS is a leading developer and provider of advanced X-ray tools used primarily in life science and materials research, as well as of X-ray and OES elemental analysis instrumentation used primarily in industrial applications. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry and also develops and provides a broad range of field analytical systems for chemical, biological, radiological and nuclear detection. Bruker Optics is a leading developer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technology. For more information, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.

MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5341254

CONTACT: Bruker BioSciences Corporation
Michael Willett, +1 978-663-3660, ext. 1411
Investor Relations and Public Relations Officer
Michael.Willett@bruker.com

SOURCE: Bruker BioSciences Corporation